More than 90 percent of human papillomavirus (HPV)-related cancers could be prevented by widespread uptake of the HPV vaccine. Yet, vaccine use in the United States falls short of public health goals.
Meningococcus group B, the most prevalent strain of meningococcal infection, is prevented with 79 per cent effectiveness in children and young adults inoculated with the 4CMenB vaccine, also known as Bexsero, according to a new collaborative study from researchers in Portugal and the UK and led by the University of Bristol which evaluated the vaccine's performance in a real-world setting. The findings are published today [1 December] in the Journal of the American Medical Association (JAMA).
KU Leuven researchers published results of their vaccine candidate, a vector vaccine based on the yellow fever vaccine. The paper shows that the vaccine protects hamsters from infection with the SARS-CoV-2 coronavirus after a single dose. It is also effective in monkeys.
The recent serious outbreak of Covid19 has required urgent medical treatments for numerous patients. No clinically active vaccines or antiviral agents are available for Covid19. According to several studies, Chloroquine (CQ) and Hydroxychloroquine (HCQ) have shown promises as Covid19 antiviral especially when administered with Azithromycin (AZM).
The findings, published in the online edition of Clinical Cancer Research on Nov. 4, 2020, suggest that BMS-986178, an investigational OX40 agonist, has an acceptable safety profile in patients with advanced solid tumors, whether used as monotherapy or in combination with the checkpoint inhibitors nivolumab (Opdivo®) and/or ipilimumab (Yervoy®).
An experimental vaccine developed in Europe to prevent infection by Crimean-Congo hemorrhagic fever virus (CCHFV) has protected cynomolgus macaques in a new collaborative study from National Institutes of Health scientists. The study, published in Nature Microbiology, comes about three years after the same research group developed the macaque model for CCHFV. No specific treatments or vaccines for CCHFV exist.
Survivors from a wide range of cancers are more likely than people in the general population to be hospitalised or die from seasonal influenza even several years after their cancer diagnosis, according to new data published in EClinicalMedicine. Given that flu and COVID-19 are both epidemic respiratory viruses with broadly similar risk factors, the findings suggest that cancer survivors are also likely to be at raised risk of severe COVID-19 outcomes.
More COVID-19 studies should be devoted to how immunity emerges to SARS-CoV-2 in the mucous membranes of the nose and mouth, a new paper argues.
In their recent research paper, published in the Feminist Legal Studies journal, City, University of London's Dr Sabrina Germain and Dr Adrienne Yong say existing barriers to medical care for these marginalised women have been intensified by the pandemic, and must be examined so as to understand their poorer health outcomes.
Scientists at Keele University and King's College London have found that 64% of people would be likely to have a COVID-19 vaccination when one became available.